Kabi Urges Caution And Patience On Subcutaneous Bortezomib Launch
As Firm Nears Pegfilgrastim Opportunities With Biosimilar Sales On Target
Fresenius Kabi’s Q1 call spanned its recent launch of a generic version of Takeda’s Velcade subcutaneous injectable to the company’s continued ambitions in biosimilars, with the German firm’s acquisition of a controlling stake in mAbxience scheduled to close by the middle of the year.
